Beacon Pointe Advisors LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 68.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,584 shares of the medical instruments supplier’s stock after selling 11,998 shares during the quarter. Beacon Pointe Advisors LLC’s holdings in Becton, Dickinson and were worth $1,375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Core Alternative Capital boosted its holdings in shares of Becton, Dickinson and by 688.2% during the 1st quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 117 shares in the last quarter. McIlrath & Eck LLC increased its position in shares of Becton, Dickinson and by 44.9% during the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 44 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Becton, Dickinson and during the 2nd quarter valued at $43,000. Elequin Capital LP purchased a new stake in shares of Becton, Dickinson and during the 1st quarter valued at $45,000. Finally, Trustcore Financial Services LLC increased its position in shares of Becton, Dickinson and by 1,346.2% during the 1st quarter. Trustcore Financial Services LLC now owns 188 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 175 shares during the last quarter. Institutional investors and hedge funds own 86.74% of the company’s stock.
Wall Street Analysts Forecast Growth
BDX has been the subject of several research analyst reports. Piper Sandler decreased their target price on Becton, Dickinson and from $255.00 to $245.00 and set a “neutral” rating for the company in a research report on Thursday, November 10th. The Goldman Sachs Group cut their price target on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. StockNews.com downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, November 11th. Finally, Evercore ISI cut their price target on Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $267.70.
Becton, Dickinson and Stock Up 0.7 %
Becton, Dickinson and (NYSE:BDX – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.74 by $0.01. The firm had revenue of $4.76 billion during the quarter, compared to the consensus estimate of $4.72 billion. Becton, Dickinson and had a return on equity of 14.47% and a net margin of 9.16%. The company’s revenue for the quarter was down 6.6% on a year-over-year basis. During the same quarter last year, the company posted $2.15 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 11.94 earnings per share for the current fiscal year.
Becton, Dickinson and Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be given a dividend of $0.91 per share. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Thursday, December 8th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.87. Becton, Dickinson and’s dividend payout ratio (DPR) is 59.18%.
Becton, Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.